---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-110303"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:53:13.003105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oruka Therapeutics enters exclusive IL-23 license with Paragon; up to $22M milestones

## Summary
- Oruka grants exclusive worldwide license for anti-IL-23 antibodies (ORKA-001) from Paragon, excluding inflammatory bowel disease.
- Milestone payments up to $22M including $1.5M for development candidate nomination and $2.5M for first Phase 1 dosing.
- Low single-digit royalty on antibody products; royalty term ends 12 years after first sale or last-to-expire patent.
- Paragon will not conduct new anti-IL-23 monospecific antibody campaigns in Field for at least 5 years.
- Company may terminate on 60 days notice; agreement also subject to material breach and insolvency provisions.

## SEC filing metadata
- accession: 0001213900-24-110303
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024110303/0001213900-24-110303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024110303/ea0225145-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-110303
- JSON: https://secwatch.observer/filing/0001213900-24-110303.json
- Plain text: https://secwatch.observer/filing/0001213900-24-110303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.